Overview

A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective was to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.
Phase:
Phase 2
Details
Lead Sponsor:
BioLite, Inc.